Abstract
An increasing incidence of moniliasis in association with the administration of the wide-spectrum antibiotics, such as aureomycin, terramycin, and chloramphenicol (chloromycetin®), has been recorded recently.1 For inclusion in New and Nonofficial Remedies, the Council on Pharmacy and Chemistry of the American Medical Association requires that these drugs bear a label warning the user that prolonged administration may lead to moniliasis.2 While cutaneous and other reactions occur with some frequency after antibiotic therapy, it is believed that incrimination of moniliasis as the cause of numerous side-reactions requires critical reappraisal. Our studies indicate that: 1. Most of the reported instances of localized moniliasis are not actually cases of this disease. 2. The definitive requirements for establishing this diagnosis are often insufficiently appreciated. 3. Infection with fungi after antibiotic therapy is a complex phenomenon that is part of the general problem of superinfection with antibiotic resistant micro-organisms, including both fungi and